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Fabry disease results from deficient a-galactosidase A (a-Gal A) activity and the pathologic accumulation of the
globotriaosylceramide (GL-3) and related glycosphingolipids, primarily in vascular endothelial lysosomes.Treatment
is currently palliative, and affected patients generally die in their 40s or 50s. Preclinical studies of recombinant
human a-Gal A (r-haGalA) infusions in knockout mice demonstrated reduction of GL-3 in tissues and plasma,
providing rationale for a phase 1/2 clinical trial. Here, we report a single-center, open-label, dose-ranging study of
r-haGalA treatment in 15 patients, each of whom received five infusions at one of five dose regimens. Intravenously
administered r-haGalA was cleared from the circulation in a dose-dependent manner, via both saturable and non-
saturable pathways. Rapid and marked reductions in plasma and tissue GL-3 were observed biochemically, his-
tologically, and/or ultrastructurally. Clearance of plasma GL-3 was dose-dependent. In patients with pre- and
posttreatment biopsies, mean GL-3 content decreased 84% in liver ( ), was markedly reduced in kidney innp 13
four of five patients, and after five doses was modestly lowered in the endomyocardium of four of seven patients.
GL-3 deposits were cleared to near normal or were markedly reduced in the vascular endothelium of liver, skin,
heart, and kidney, on the basis of light- and electron-microscopic evaluation. In addition, patients reported less
pain, increased ability to sweat, and improved quality-of-life measures. Infusions were well tolerated; four patients
experienced mild-to-moderate reactions, suggestive of hypersensitivity, that were managed conservatively. Of 15
patients, 8 (53%) developed IgG antibodies to r-haGalA; however, the antibodies were not neutralizing, as indicated
by unchanged pharmacokinetic values for infusions 1 and 5. This study provides the basis for a phase 3 trial of
enzyme-replacement therapy for Fabry disease.
Introduction
Fabry disease (MIM 301500) is an X-linked inborn error
of glycosphingolipid catabolism resulting from the de-
ficient activity of the lysosomal exoglycohydrolase, a-
galactosidase A (a-Gal A) (Desnick et al. 1995, 2001).
In patients with the classical disease phenotype, the pro-
gressive accumulation of globotriaosylceramide (GL-3)
and related glycosphingolipids, particularly in vascular
endothelial lysosomes in the heart, liver, kidney, skin,
and brain, leads to the major disease manifestations.
Clinical onset occurs in childhood or adolescence and is
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characterized by severe acroparesthesias, angiokera-
toma, corneal and lenticular opacities, and hypohidrosis.
With advancing age, renal failure and vascular disease
of the heart and brain lead to early demise, the average
age at death being 41 years in one series (Colombi et
al. 1967). To date, there is no specific therapy for Fabry
disease, and treatment is supportive, limited to symp-
tomatic management of the acroparesthesias and epi-
sodes of excruciating pain and of complications of renal
failure, cardiac, or cerebrovascular disease.
It is of relevance that patients with residual a-Gal A
activity (∼1% to ∼10% of normal) are essentially
asymptomatic or have a mild form of the disease limited
to cardiac involvement (von Scheidt et al. 1991; Desnick
et al. 2001). These “cardiac variants” typically present
in late adulthood (140 years) with left ventricular hy-
pertrophy, cardiomyopathy, and/or mild proteinuria.
They lack the classic disease manifestations, which in-
clude angiokeratoma, acroparesthesias, hypohidrosis,
corneal/lenticular dystrophy, and renal failure. A con-
sistent feature of the cardiac variant is the absence of
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Table 1
Summary of Patient Demographics
DOSE
REGIMEN
MEAN AGE
(RANGE)
(years)
MEAN
WEIGHT
(RANGE)
(kg)
RACE (n)
White Hispanic
0.3 mg/kg/14 d 41.0 (35–44) 64.7 (57–71) 3 0
1.0 mg/kg/14 d 33.7 (27–38) 73.6 (57–88) 1 2
3.0 mg/kg/14 d 34.7 (32–37) 69.1 (56–82) 2 1
1.0 mg/kg/48 h 27.0 (18–37) 69.8 (65–73) 2 1
3.0 mg/kg/48 h 35.7 (30–45) 78.0 (67–93) 3 0
lysosomal glycosphingolipid accumulation in the vas-
cular endothelium (Elleder et al. 1990; von Scheidt et
al. 1991), the pathogenic hallmark of classically affected
patients (Desnick et al. 2001). The cardiac variants dem-
onstrate that even low levels of a-Gal A activity can
markedly alter the classic disease phenotype, particu-
larly the morbidity associated with the progressive vas-
cular endothelial glycosphingolipid deposition.
Early pilot trials of enzyme replacement in classically
affected males involved the intravenous administration
of either a single dose of fresh normal plasma containing
active a-Gal A (Mapes et al. 1970) or a single dose of
the partially purified placental enzyme (Brady et al.
1973). These studies demonstrated that intravenously
infused enzyme from plasma or placenta could decrease
the level of accumulated plasma GL-3. In a subsequent
study, two affected brothers each received six doses of
a-Gal A purified from splenic tissue or plasma over a
3-mo period (Desnick et al. 1979). The splenic-derived
enzyme was cleared rapidly from the circulation (t1/2
∼10 min), transiently decreasing the circulating GL-3
concentration, whereas the more highly sialylated
plasma-derived enzyme had a slower clearance ( ∼70t1/2
min) and effected a longer depletion of circulating GL-
3. Notably, two doses of the plasma-derived enzyme,
administered on days 1 and 3, reduced the plasma sub-
strate level into the normal range (Desnick et al. 1980).
These studies demonstrated the feasibility of enzyme-
replacement therapy for Fabry disease; however, the dif-
ficulty of producing enough purified enzyme for clinical
trials was a major obstacle.
This obstacle was overcome following the isolation
of the human a-Gal A cDNA (Bishop et al. 1986) and
demonstration of its high-level expression in Chinese
hamster ovary (CHO) cells (Ioannou et al. 1992),
thereby providing a source of both lysosomal (oligo-
saccharide processed) and secreted (highly-sialylated)
glycoforms of the enzyme (Matsuura et al. 1998). In
addition, the generation of knockout “Fabry mice”with
a-Gal A deficiency (Wang et al. 1996) permitted deter-
mination, by preclinical studies, of the pharmacokinet-
ics and biodistributions of various recombinant human
a-Gal A (r-haGalA) glycoforms (Ioannou et al. 2001).
When a highly sialylated glycoform (AGA-1) was used,
these animal-model studies demonstrated a dose-depen-
dent clearance of accumulated GL-3 from the circula-
tion and from the pathologic sites of substrate deposi-
tion in the liver, heart, kidney, and skin (Ioannou et al.
2001), thereby establishing “proof of concept” for clin-
ical trials of r-haGalA replacement in patients with Fa-
bry disease. In addition, in a recent phase 1 study, single
doses of recombinant enzyme reduced GL-3 levels in
liver and urinary sediment (Schiffmann et al. 2000).
Here, we report the results of a phase 1/2 trial of five
dose regimens of r-haGal A in 15 classically affected
males with Fabry disease. This open-label dose-escala-
tion study was conducted to evaluate the safety and
pharmacokinetics of r-haGalA infusions and to provide
preliminary efficacy data for enzyme-replacement ther-
apy in this lysosomal-storage disease.
Material and Methods
Study Design
Fifteen classically affected male patients with Fabry
disease were recruited for this multidose, open-label, sin-
gle-center, dose-escalation study of r-haGalA (Fabra-
zyme [agalsidase beta]; Genzyme). Participants were
aged16 years and had a-Gal A activity in plasma !1.5
nmol/h/ml, GL-3 concentrations in plasma 5.0 ng/ml,
serum creatinine !2.5 mg/dl, and no history of renal
dialysis or transplantation. Patients were sequentially en-
rolled into one of five r-haGalA dosing regimens with
three patients per group. The characteristics of the five
groups are shown in table 1. Patients in each group
received five doses of enzyme as follows: Group A, 0.3
mg/kg of r-haGalA every 14 d (biweekly); Group B, 1.0
mg/kg biweekly; Group C, 3.0 mg/kg biweekly; Group
D, 1.0 mg/kg every 48 h; and Group E, 3.0 mg/kg every
48 h. R-haGalA was synthesized in CHO cells, and the
secreted homodimeric enzyme was purified from the
growth medium. Each enzyme subunit contained three
glycosylation sites, with the predominant oligosacchar-
ides being bi- and monophosphorylated oligomannose
structures and sialylated complex structures. Enzyme
was diluted to 100 ml with saline, and infusions were
given intravenously at a rate of 0.83 ml/min. The insti-
tutional review board of theMount Sinai School ofMed-
icine approved the study, and all patients gave written
informed consent to participate in the study.
Clinical Assessments
Medical and safety evaluations—including medical
history, physical examinations, vital signs, routine serum
and urine chemistries, hematology indices, and
EKGs—were performed at baseline, prior to each in-
fusion, and after infusion 5. In addition, echocardi-
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ograms and renal magnetic resonance imaging (MRI)
were evaluated at baseline and after infusion 5. Patients
completed the Short Form McGill Pain Survey (Melzack
1987) and the Short Form–36 (SF-36) Health Survey
(Ware et al. 1997) to assess quality-of-life measures at
baseline and after infusion 5. Patients continued their
usual prophylactic and analgesic pain medications. Ad-
verse events were coded using the World Health Organ-
ization Adverse Reactions Thesaurus (WHOART). At
baseline, prior to each infusion, and after infusion 5, an
enzyme-linked immunosorbent assay (ELISA), specific
for r-haGalA, and a confirmatory radioimmunoprecip-
itation technique were used to assess antibody response
to r-haGalA.
Molecular and Biochemical Studies
Specific mutations in the a-Gal A gene in each patient
were previously determined (e.g., Eng et al. 1993).
Plasma and tissue a-Gal A activities weremeasuredusing
2.5 mM 4-methyumbelliferyl-a-D-galactoside as sub-
strate (Desnick et al. 1973). Plasma and tissue GL-3
concentrations were measured using a verotoxin-based
ELISA specific for GL-3 (Zeidner et al. 1999). Plasma
GL-3 levels were measured at baseline, before each in-
fusion, and either 14 d (for the every-48-h groups) or
21–28 d (for the biweekly groups) after infusion 5.
Collection of Tissue Samples
Percutaneous needle biopsies of liver and 3-mm punch
biopsies of skin from the lower back (avoiding angio-
keratomas) were collected from all patients at baseline
and 2–3 d after infusions 1 and 5. Pre- and posttreatment
right-ventricular endomyocardial and kidney biopsies
were optional procedures for a subset of participants in
groups C, D, and E only. Tissue samples were divided
and then prepared for light and electron microscopy or
frozen at 80C for biochemical analyses.
Pharmacokinetic Analyses
For infusions 1 and 5, r-haGalA activity was deter-
mined from blood samples collected at 30, 60, and 90
min during the infusions and at multiple time points
0–480 min after these infusions. These data were eval-
uated using standard noncompartmental analysis. In ad-
dition, concentration-time data were subjected tomodel-
independent pharmacokinetic analysis. The following
pharmacokinetic values were determined: (1) area under
the curve (AUC0–), as computed by the linear trape-
zoidal rule; (2) area under the moment (AUMC0–); (3)
peak a-Gal A concentration ( ); (4) time to peakCmax
activity ( ); (5) the terminal elimination half-lifeTmax
( ); (6) volume of distribution at steady state (VSS);t1/2
(7) clearance; (8) mean residence time extrapolated to
infinity (MRT); and (9) the elimination-rate constant
( ).lZ
Histological Evaluations
For light microscopy, tissue was embedded in paraffin
(liver, kidney, and skin), glycomethacrylate (kidney), or
Epon (skin and heart). Sections were stained with he-
matoxylin and eosin (liver, kidney), periodic acid-Schiff
(liver, skin, and kidney), methylene blue/azure II (skin,
heart, kidney), and/or oil red O (skin). For electron mi-
croscopy, gluteraldehyde-fixed tissue was posttreated
with OsO4, was epoxy-embedded, was sectioned (4–5
mm), and was viewed under a JOEL transmission elec-
tron microscope. Representative tissue specimens were
photographed. Scoring of tissue response to treatment
was performed with coded instruments designed by
expert pathologists for light- and electron-microscopic
assessment of the tissue and cell types with significant
GL-3 accumulation. Quantitation of GL-3 content for
both light and electron microscopy was based on a 4-
point scoring system to evaluate the degree and extent
of glycosphingolipid inclusions (ranging from 0, normal
or near normal, to 3, severe involvement). This system
was applied to several structures in each tissue. Excep-
tions to this format were an extended coding range for
the vascular endothelium of the skin (0–5) to account
for any accidental inclusion of angiokeratomatous ves-
sels in the biopsy, and a histomorphometric method ap-
plied to the tightly grouped inclusions in cardiomyocytes
with scores expressed as the volume of inclusions relative
to the total volume of tissue evaluated.
Statistical Analyses
Statistical analyses were performed using the Statis-
tical Software System (SAS Institute). The SF-36 ques-
tionnaire was analyzed using the SF-36 health scoring
system (Ware et al. 1997). A Wilcoxan signed rank test
was used to calculate change from baseline for quality
of life and pain (Short FormMcGill Pain Questionnaire)
values (Melzack 1987).
Results
Pharmacokinetics
Concentration-time data for r-haGalA infusions dem-
onstrated a dose-dependent (nonlinear) profile consistent
with enzyme clearance from the circulation via both sat-
urable and nonsaturable (concentration-independent)
pathways. Semilog plots of mean concentration-time
data for the first 2 h of infusion of r-haGalA at doses
of 0.3, 1.0, or 3.0 mg/kg biweekly (groups A–C) are
shown in figure 1. Mean plasma concentrations reached
80% of peak values 60 min into the infusion for the 0.3
mg/kg dose (group A) and 90 min into the infusion for
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Figure 1 Pharmacokinetics of r-haGalA infusions. Semilog plots
of mean concentration-time data for r-haGalA infusions at doses of
0.3 (), 1.0 (●), or 3.0 () mg/kg (groups A–C), demonstrating the
dose-dependent (nonlinear) profile consistent with enzyme cleared
from the circulation via both saturable and nonsaturable (concentra-
tion independent) pathways. R-haGalA was infused over 120 min. See
text for details.
Figure 2 Effect of r-haGalA dose on plasma GL-3 clearance.
Individual patient plasma GL-3 concentrations determined just prior
to infusions 1–5 for the 0.3 (A), 1.0 (B), and 3.0 (C) mg/kg biweekly
dosing groups.
the 1.0 and 3.0 mg/kg doses (groups B and C). When
infusions were completed, mean concentrations dropped
to half-peak values within 15, 20, and 45 min for the
0.3-, 1.0-, and 3.0-mg/kg dose groups, respectively.
Clearance appeared to be biphasic for all biweekly dose
groups, with the more rapid elimination phase lasting
1–2 h after infusion. AUC values were increased dis-
proportionately with dose, from ∼80 to ∼500 to ∼4000
mg/min/ml. The mean VSS had a range of 80–330 ml/
kg (1–4 times blood volume). Clearance decreased from
4 ml/min/kg to ∼1 ml/min/kg with increasing dose. Of
note, the terminal elimination half-life was not affected
by dose, which is consistent with elimination being gov-
erned, in part, by a first-order, concentration-indepen-
dent mechanism.
Plasma GL-3 Clearance was Dose-Dependent
Plasma GL-3 concentrations were reduced in a dose-
dependent manner for all infusion groups (fig. 2). Prior
to treatment, all patients had elevated plasma GL-3 lev-
els, with a range of 2.0–53.9 ng/ml (mean 17.1 12.8
ng/ml; the normal, undetectable level is !1.2 ng/ml).
Plasma GL-3 levels in patients receiving r-haGalA at 0.3
mg/kg biweekly tended to decrease with each dose,
reaching their lowest values only at infusion 5. In con-
trast, plasma GL-3 levels in all three patients receiving
r-haGalA at doses of 3.0 mg/kg biweekly totally cleared
after the first infusion and remained undetectable
throughout the clinical trial. Two of three patients re-
ceiving r-haGalA at 1.0 mg/kg biweekly demonstrated
plasma GL-3 clearance after the first infusion, whereas
the third patient’s plasma GL-3 level was reduced but
never reached undetectable levels. In patients receiving
1.0 or 3.0 mg/kg every other day (groups D and E), the
plasma GL-3 levels were lowest at infusion 4; however,
the decreases were less than those observed in patients
with biweekly dosing schedules (data not shown).
Tissue GL-3 Clearance Was Dose- and Organ-
Dependent
Liver.—Hepatic GL-3 concentrations, measured by
ELISA, were reduced by an average of 84% in the 13
patients who had pre- and posttreatment liver biopsies.
As shown in table 2, GL-3 clearance was particularly
consistent and profound (mean clearance 92%) in group
C patients, who received 3.0 mg/kg biweekly. However,
marked GL-3 reductions were observed in all dose co-
horts. Histologic scores from electron-microscopic eval-
uations based on the 0–3 scale confirmed the positive
response to r-haGalA treatment, with reductions in
mean sinusoid endothelial GL-3 accumulation scores
from ( ) at baseline to2.40 0.74 np 15 0.5 0.52
( ) after infusion 5. Mean Kupffer cell scores de-np 14
creased from ( ) to2.80 0.56 np 15 1.07 0.27
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Table 2
GL-3 Clearance in Liver, Heart and Kidney
TISSUE,
DOSE
REGIMEN,
AND
PATIENT
AGE
(years)
a-Gal A
MUTATION
GL-3 CONCENTRATION
REDUCTION
(%)
at Baseline
(ng/mg tissue)
2–5 d after
Infusion 5
Liver:
Group A:
2 44 C56G 870 74 91
3 44 N263S 1,130 48 96
Group B:
4 27 W287C 832 185 78
5 36 C172Y 176 134 24
6 38 C172Y 2410 45 98
Group C:
7 32 W226R 371 26 93
8 37 G138E 1,780 153 91
9 35 L89R 352 29 92
Group D:
10 37 G138E 12,650 5,940 53
11 26 R227Q 1,280 38 97
12 18 W95S 1,640 77 95
Group E:
13 45 1118 insT 1,690 204 88
15 32 26delA 140 0 100
Heart:
Group C:
7 32 W226R 17,600 15,700 11
8 37 G138E 38,100 40,900 7
9 35 L89R 17,500 12,900 26
Group D:
10 37 G138E 32,500 29,800 8
11 26 R227Q 17,800 14,800 17
12 18 W95S 8,320 10,700 29
Group E:
13 45 1118 insT 25,000 48,100 93
Kidney:
Group C:
8 37 G138E 12,930 384 97
9 35 L89R 6,910 512 93
Group D:
10 37 G138E 1,060 448 58
11 26 R227Q 10,100 1,980 80
Group E:
13 45 1118 insT 1,860 5,630 203
( ). A dose effect was observed for endothelial GL-np 14
3 clearance in dosing cohorts treated biweekly: from
baseline, mean scores decreased points for1.67 0.58
the 0.3-mg/kg group A, points for the 1.02.00 1.00
mg/kg group B, and, points for the 3.0-2.33 1.15
mg/kg group C. Notably, one patient in Group E had
increased sinusoid and Kupffer cell scores and was not
included in the histologic analysis.
Skin.—Low and variable GL-3 levels were detected by
ELISA in pretreatment skin biopsies (mean 350 168
ng/mg of tissue; range 128–803 ng/mg tissue). Following
infusion 5, the mean GL-3 concentration decreased
∼40%, to ng/mg of tissue. Of the 14 patients191 160
with paired samples, 11 had reductions, and 3 (1 from
group A and 2 from group D), had increases from
baseline.
Pre- and posttreatment skin biopsies were obtained,
free of angiokeratomas, for all patients. Histological
evaluation resulted in scores of3 on the expanded 0–5
scale, except in one patient, who had a baseline capillary
endothelial score of 4 (fig. 3A). In histologic sections
stained with periodic acid-Schiff, markedly reduced
mean GL-3 scores were observed in the endothelium of
superficial capillaries (from at baseline to2.6 0.79
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Figure 3 Light-microscopic assessment of the vascular endothe-
lial GL-3 deposits in skin (A), heart (B), and kidney (C), before and
after r-haGalA treatment by expert pathologists blinded to time of
biopsy and patient. A, Pre- and posttreatment GL-3 scores (ranging
from 0, normal or near normal, to 4, severe) of skin capillary endo-
thelium for 14 patients. Note that the seven with paired pre- and
posttreatment biopsies all cleared their capillary endothelial GL-3 de-
posits (“0” scores). B, Pre- and posttreatment endomyocardial vascular
endothelium GL-3 scores (ranging from 0, normal or near normal, to
3, severe) for seven patients: three in group C, three in group D, and
one in group E. Note that the seven patients with paired pre- and
posttreatment biopsies all had reduced GL-3 scores and four had
cleared their capillary endothelium (“0” scores). C, Pre- and post-
treatment GL-3 scores (ranging from 0, normal or near normal, to 3,
severe) for kidney vascular endothelium for seven patients: three in
group C, two in group D, and two in group E. Note that the two with
paired pre- and posttreatment biopsies had cleared their capillary en-
dothelial GL-3 deposits (“0” scores). See text for details.
after infusion 5), with the greatest improve-0.11 0.33
ment in patients in the biweekly dose cohorts. Clearance
was observed with all dose regimens, best demonstrated
overall by immunohistochemistry (figs. 4A and 4B). For
the perineurium, five of eight patients with paired bi-
opsies showed decreases of 1 or 2 points from baseline.
In the deeper arterioles, endothelial scores varied, with
three of six patients declining by 1 or 2 points and the
others remaining unchanged. Electron-microscopic eval-
uations provided similar results, with mean scores for
GL-3 deposits in endothelial cells of superficial capil-
laries decreasing from at baseline to2.80 0.41
after infusion 5. Of 12 patients in treatment0.50 0.65
groups B–E, 8 essentially cleared all the accumulated
GL-3 from the endothelium, achieving scores of 0 after
the last infusion (e.g., figs. 4C and 4D). Similarly, mean
GL-3 scores in the endothelium of deeper arterioles
showed consistent decreases ( at baseline to3.00 0.0
; ). In contrast, GL-3 deposits in per-1.50 1.00 np 14
icytes, perineurium, and the muscular layer of arterioles,
as well as the histiocytes and fibrocytes, showed little or
no change.
Heart.—Endomyocardial biopsies were obtained pre-
and posttreatment in seven patients from groups C, D,
and E. As shown in table 2, baseline tissue GL-3 levels,
determined by ELISA, were high, with a range of
8,320–38,100 ng/mg tissue (mean ng/21,400 7,420
mg tissue). Following infusion 5, the mean GL-3 con-
centration decreased only slightly (15.6%) to
ng/mg tissue in four patients with de-18,300 7,780
creases. Histologic scores for the capillary endothelium,
assessed by light microscopy (fig. 3B), decreased in all
seven patients with pre- and posttreatment biopsies;
mean scores decreased from at baseline to1.75 0.89
after treatment. By electron-microscopic0.57 0.79
examination (e.g., figs. 5A and 5B), six of seven paired
biopsies had decreased scores for vascular endothelial
GL-3, whereas one patient’s scores remained unchanged
(mean scores of 2.14 and 0.71, pre- and posttreatment,
respectively). After five infusions, GL-3 storage remained
unchanged in the cardiomyocytes, pericytes, and vas-
cular smooth muscle.
Kidney.—Paired pre- and posttreatment kidney bi-
opsies were obtained from five patients: two each in
groups C and D, and one in group E. Pretreatment kid-
ney GL-3 concentrations, determined by ELISA, varied
considerably (table 2), with a range of 1,060–12,900 ng/
mg tissue (mean ng/mg; ). Follow-5,530 4,580 np 5
ing infusion 5, the mean GL-3 level was decreased by
67.6% to ng/mg in the five patients with1,790 2,250
paired samples. Four patients decreased their levels by
a mean of 84% (mean ng/mg), whereas the830 770
fifth patient’s level almost doubled. Sampling variability
may account for part of this discrepancy.Histologic eval-
uations focused on four functional areas known to har-
bor prominent GL-3 inclusions: glomeruli, tubules, in-
tertubular interstitium, and larger multilayered vessels.
There was a consistent pattern of reduction of GL-3
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Figure 4 A and B, Immunohistochemistry for GL-3 in skin with verotoxin subunit B. Comparison of pretreatment (A) and posttreatment
(B) photomicrographs shows that r-haGalA treatment resulted in marked clearance of GL-3 inclusions, particularly from the superficial vas-
culature of the papillary dermis. C and D, Electron micrographs of single superficial capillaries of the skin. Before treatment (C), the capillary
endothelium was heavily laden with lamellar glycosphingolipid inclusions (arrows). After treatment (D), the endothelium of superficial capillaries
was cleared of GL-3 inclusions (arrow). See text for details.
inclusions in the three vascular beds. As shown in figure
3C,GL-3 accumulation in the endothelium of interstitial
capillaries declined in four of five patients (e.g., fig.
6A–6D) but increased in one. In two patients with paired
glomerular capillary scores, endothelial GL-3 scores de-
clined from 2 to 0 and from 1 to 0, respectively. For the
arterioles, four paired samples showed declines in en-
dothelial GL-3 content of1 point (mean scores of 2.25
at baseline to 1.00 after treatment).
Response in other tissue types varied considerably.
Prominent reductions occurred following treatment in
glomerular mesangial cells (from 2.00 at baseline to 0.00
in group C; ) and in cortical interstitial cells (2.60np 2
at baseline to 1.00 in groups C, D, and E; ). Thenp 5
distal convoluted tubules and collecting ducts that, along
with the glomerular podocytes, had the most prominent
GL-3 storage in the kidney at baseline were difficult to
evaluate but appeared to trend to reduced scores. The
glycosphingolipid deposits in the glomerular podocytes
appeared unresponsive to treatment. Electron-micro-
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Figure 5 Photomicrographs of interstitial capillaries of the myocardium before (A) and after (B) treatment (methylene blue/azure II stain).
Pretreatment (A), small-to-medium–sized glycosphingolipid inclusions were seen in the endothelium of small interstitial capillaries (arrows; score
2). After treatment (B), glycosphingolipid inclusions were cleared from the endothelium of small capillaries (arrows). The GL-3 inclusions in
the cardiomyocytes (arrowheads) were less responsive to treatment. See text for details.
scopic evaluations, performed on a small number of sam-
ples, supported the findings from light microscopy.
Clinical Findings
Pre- and posttreatment EKGs, echocardiograms, and
renal MRIs were unchanged. Patients anecdotally re-
ported an increased ability to sweat and less fatigue. Pain
was assessed by the Short Form McGill Pain Question-
naire. Compared to the pretreatment baseline results, the
“overall pain” and “present pain intensity” scores were
significantly improved after five infusions at all doses
( and , respectively). In addition, thePp .03 Pp .004
SF-36 quality-of-life questionnaire indicated improve-
ment posttreatment for three indices: bodily pain, gen-
eral health, and vitality.
Safety Evaluation
Of the 15 patients, 13 completed all five r-haGalA
infusions, which were generally well tolerated. The most
common adverse event was a transient mildly-to-mod-
erately increased blood pressure during infusions, which
did not require treatment and returned to normal during
or immediately after infusion. There were no significant
changes in blood indices or blood and urine chemistries.
Patient 14 (group E), who had discontinued a 7-mo an-
ticoagulant treatment for a deep vein thrombosis of a
lower extremity prior to joining the study, complained
of mild chest pain the day after he received his last r-
haGalA infusion. He was diagnosed with a pulmonary
embolus, was retreated with anticoagulant therapy, and
recovered without complication.
Of 15 patients, 8 developed IgG antibodies specific to
r-haGalA. Of these, the four who experienced symptoms
compatible with hypersensitivity-type reactions had
seroconverted. Two of these patients (patient 5, group
B, and patient 7, group C), had symptoms suggestive of
allergic reactions during infusion 4 and did not tolerate
reinfusion, whereas the other two patients were suc-
cessfully retreated. Importantly, despite this antibody re-
sponse, mean pharmacokinetic values did not change
between the first and fifth infusions for all patients stud-
ied (fig. 7).
Discussion
The primary finding of this phase 1/2 trial was that in-
fused r-haGalA safely and effectively cleared the accu-
mulated GL-3 from endothelium of the liver, skin, heart,
and kidney—major sites of pathology in classical Fabry
disease. The demonstration that lysosomal glycosphin-
golipid accumulation in the microvasculature and other
cell types was reversible provided “proof of principle”
for enzyme-replacement therapy in this disease. Since
Figure 6 Light and electron micrographs of kidney pre- and posttreatment (methylene blue/azure II stain). A and B, Light microscopy of
capillaries in the intertubular interstitium. Before treatment (A), the capillary endothelium (arrows) is heavily laden with glycosphingolipid
inclusions, some impinging on the lumen (score 3). After treatment (B), most of the capillaries (arrows) have been cleared of glycosphingolipid
inclusions (score 0). C and D, Electron micrographs of kidney cortex with examples of an intertubular capillary (arrow) and neighboring distal
convoluted tubule (arrowhead). Before treatment (C), numerous electron-dense glycosphingolipid inclusions are seen in the capillary endothelium
(small arrow). In the adjacent distal convoluted tubule, the epithelium is heavily packed with numerous electron-dense lamellar lysosomal
inclusions (small arrowhead). After treatment (D), the endothelium of a small capillary (arrow) has no evidence of glycosphingolipid inclusions.
In the adjacent distal convoluted tubule (arrowhead), the number and distribution of lysosomal inclusions appear similar; however, the lamellar
architecture of the individual lysosomes appears less tightly organized (small arrowhead), suggesting enzymatic hydrolysis of the accumulated
GL-3.
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Figure 7 Comparison of the pharmacokinetics of r-haGalA for
infusions 1 and 5. Comparison of mean concentration-time data for
groups A and B. R-haGalA was infused over 120 min. Infusion 1:
group A (●), group B (); infusion 5: group A (), group B (#). See
text for details.
“cardiac variants” with Fabry disease lack microvas-
cular glycosphingolipid accumulation and the major
clinical manifestations of classically affected patients (El-
leder et al. 1990; von Scheidt et al. 1991; Desnick et al.
2001), it is anticipated that the clearance of GL-3 from
the microvasculature and other tissue sites of pathology
should lead to significant physiologic and clinical
improvement.
Beyond the microvascular GL-3 clearance, the gly-
cosphingolipid tissue load and response to r-haGalA
treatment varied. Presumably, the different cellular gly-
cosphingolipid levels reflected endogenous glycosphin-
golipid synthesis and cell turnover rates, whereas the
differential clearance was a function of cellular and ly-
sosomal enzyme uptake and stability. In the liver, which
had the highest uptake of enzyme on the basis of the
preclinical studies in “Fabry mice” (Ioannou et al.
2001), all dose regimens markedly reduced GL-3 levels;
there was an 84% mean clearance of hepatic GL-3 by
ELISA in patients with pre- and posttreatment biopsies
(table 2). Morphologic examination revealed that the
two principal hepatic reservoirs of glycosphingolip-
id—the endothelial cells of the sinusoids and the Kupffer
cells—were almost totally cleared of glycosphingolipid
inclusions. In comparison to other tissues studied, base-
line endomyocardial GL-3 levels were the highest of
those in all tissues studied, an order of magnitude
greater than those in kidney (table 2). Histologic anal-
ysis revealed that the majority of GL-3 accumulation
was in the cardiomyocytes and that the storage was not
remarkably changed after five doses of r-haGalA at 1
or 3 mg/kg. Similar results were documented by the
ELISA determinations (table 2). Longer-term enzyme
replacement presumably is required to reduce the sub-
stantial GL-3 accumulation in cardiomyocytes. Of note,
preclinical studies in the “Fabry mouse” indicated that
r-haGalA activity was detectable in the heart when 3.0
mg/kg was infused (Ioannou et al. 2001).
Although the number of paired pre- and posttreat-
ment renal biopsies for histologic analysis was limited,
all three vascular beds showed the same response to
treatment, a prominent reduction in GL-3 content from
the endothelium. Total renal GL-3 levels, determined by
ELISA, in four of the five patients with pre- and post-
biopsy data also revealed a mean 82% reduction after
treatment. Because the total vascular GL-3 content is a
relatively small component of the total renal GL-3 ac-
cumulation, and because the podocyte inclusions were
unchanged, most of the GL-3 reduction must have been
from the tubules, the only other major storage site.
Taken together with the reduction in vascular endothe-
lial GL-3 levels, these results suggest potential benefit
for kidney function.
In general, the biochemical and histologic assessments
indicated that GL-3 clearance was dose and tissue-de-
pendent, analogous to the findings of r-haGalA replace-
ment in “Fabry mice” (Ioannou et al. 2001). The bi-
weekly dose regimens proved to be more effective than
the every 48 h regimens, the latter included to assess
the effects of a rapid, high-dose schedule (i.e., a “loading
dose”), similar to that used in the preclinical studies
(Ioannou et al. 2001). It was reasoned that administra-
tion every 48 h would achieve the highest enzyme con-
centration in lysosomes and the greatest plasma and
tissue GL-3 clearance, particularly since the tissue half-
life of the enzyme in the “Fabry mouse” was 2–4 d.
However, the biweekly regimens unexpectedly cleared
more substrate, the 1- and 3-mg/kg doses being more
effective than the 0.3-mg/kg dose. Although assessment
of GL-3 clearance in heart and kidney was limited, be-
cause of the small number of optional paired biopsies
from patients in groups C–E, the greatest clearance was
observed in patients in group C, who received 3 mg/kg
biweekly. In addition, there was a direct effect of dose
on plasma GL-3 levels. For example, plasma GL-3 was
cleared from the circulation after the first infusion in
patients in the 1.0- and 3.0-mg/kg biweekly dosing
groups (fig. 2), whereas plasma GL-3 levels in the 0.3-
mg/kg dosing group decreased with each infusion,
reaching their lowest levels at infusion 4 or 5. Of in-
terest, GL-3 reaccumulation in the plasma and tissues
of “Fabry mice” following a single r-haGalA dose (3
mg/kg) suggest that the plasma GL-3 level might reflect
the total body load of substrate (Ioannou et al. 2001).
Analogously, the plasma GL-3 concentration may pro-
vide a noninvasive indicator of tissue GL-3 clearance in
patients with Fabry disease.
Clinically, the patients reported decreased pain and
an increased ability to sweat, both findings consistent
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with GL-3 clearance from microvascular endothelial
cells. Improvements in several quality-of-life measures
also were noted. However, assessments of pain and
quality of life require more rigorous evaluation in a
larger, double-blind study, to minimize possible placebo
effects.
This phase 1/2 clinical trial also evaluated the safety
of r-haGalA infusions. Although the enzyme infusions
were generally well tolerated, it was expected that most
patients would raise antibodies to r-haGalA, since clas-
sically affected males with Fabry disease are cross-re-
active immunological material–negative for the a-Gal
A protein (Desnick et al. 2001). In fact, four patients
had mild-to-moderate hypersensitivity-type reactions:
two with transient fever and chills, one with hives, and
one with tachycardia. Although they responded to
symptomatic treatment, two of these four patients were
unable to complete their fifth infusions. Immunologic
studies revealed that six (67%) of the nine patients on
the biweekly dosing schedule seroconverted after the
second or third infusion, whereas two (33%) of six
patients on the every-48-h regimens seroconverted after
the fifth infusion (day 9). In all cases, seroconversion
was an IgG response, and almost identical pharmaco-
kinetic profiles at the first and last infusions for both
biweekly (fig. 7) and every-48-h (data not shown) in-
fusion schedules indicated that antibodies were not neu-
tralizing. Also, urine chemistry, blood cytology, and tis-
sue-histology results were not altered in response to
adverse reactions associated with enzyme infusions. On
the basis of these findings and of previous experience
with management of enzyme infusions for Gaucher dis-
ease (Grabowski et al. 1998; Mistry 1999), pretreat-
ment with antipyretics and antihistamines, as well as
decreasing the rate of infusion, are recommended for
subsequent studies.
The most common adverse event associated with en-
zyme administration was a mild, transient increase in
blood pressure, which did not require medical inter-
vention or prevent patients who entered the trial with
hypertension from safely completing their infusions.
Only two serious adverse events occurred, and of these
only one, an allergic reaction, was attributable to
r-haGalA administration. The other serious adverse
event was a pulmonary embolism in a patient who re-
cently discontinued anticoagulation treatment for a pre-
vious deep vein thrombosis. Of the other recorded ad-
verse events, none was attributed to enzyme
administration; however, several were associated with
biopsy procedures.
In summary, the phase 1/2 clinical trial of r-haGalA
replacement in classically affected patients with Fabry
disease demonstrated that the infused enzyme generally
was well tolerated and that the expected infusion re-
actions following seroconversion were mild and con-
servatively managed. This trial provided the “proof of
principle” that enzyme replacement could reverse the
GL-3 accumulation in key sites of pathology. These re-
sults also indicated that the clearance of GL-3 from
tissue lysosomes was dose-dependent and that enzyme
could reach and hydrolyze the accumulated GL-3 in
lysosomes. Finally, these studies provide the basis for a
phase 3 pivotal trial with a greater number of patients
to further evaluate the safety and efficacy of r-haGalA
replacement in Fabry disease.
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